Favilar 200 mg (Tablet)
Unit Price: ৳ 200.00 (2 x 10: ৳ 4,000.00)
Strip Price: ৳ 2,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Favipiravir |
| Company | Popular pharmaceuticals ltd |
Indications
- Treatment of novel or re-emerging pandemic influenza virus infections
Description
- Approved for manufacture and sale in Japan as an influenza antiviral
- Selective inhibition of the RNA polymerase of the influenza virus
- Potential effectiveness in treating COVID-19
- Only used when other influenza antiviral drugs are ineffective
- Discretion of Japan’s Health, Labor and Welfare Ministry for production and distribution
- Not available at hospitals and pharmacies in Japan or overseas
Pharmacology
- Metabolized into favipiravir ribosyl triphosphate by an intracellular enzyme
- Selective inhibition of RNA polymerase of the influenza virus
- Effective against all types and sub-types of human influenza A, B, and C viruses
- Wide range of anti-viral activity against various influenza virus strains including avian and swine viruses
Dosage & Administration
- Usual adult dosage: 1600 mg orally twice daily on Day 1, followed by 600 mg orally twice daily from Day 2 to Day 5
- Total treatment duration: 5 days
Interaction
- In animal studies: decreased RBC production, increases in liver function parameters such as AST, ALP, ALT, and total bilirubin, and increased vacuolization in hepatocytes
- Toxicity information regarding Favilar in humans not readily available
Contraindications
- Contraindicated for pregnant women and women who may possibly be pregnant
Side Effects
- Most common side effects: Diarrhea and increase of blood uric acid levels
Pregnancy & Lactation
- May cause delayed development or death of embryos during the early stage of pregnancy
- Should not be given during pregnancy
Precautions & Warnings
- Should not be given in pregnant women
- Requirement of confirmation of non-pregnancy in women of childbearing potential before use
- Thorough contraception measures from the start of the treatment to 7 days after the end of the treatment
- Caution for Hepatic and renal impaired patient
Use in Special Populations
- Experimental drug
- Studies needed about efficacy, toxic reactions, and use in children
Overdose Effects
- In animal studies: decreased RBC production, increases in liver function parameters such as AST, ALP, ALT, and total bilirubin, and increased vacuolization in hepatocytes
- Toxicity information regarding Favilar in humans not readily available
Therapeutic Class
- Anti-viral drugs
Storage Conditions
- Keep below 30°C temperature
- Protected from light & moisture
- Keep out of the reach of children